摘要【目的】探讨乳腺癌术后接受内分泌治疗的患者发生子宫内膜癌的危险因素。【方法】回顾性分析2015年1月至2020年3月本院收治的288例乳腺癌术后接受内分泌治疗出现子宫内膜病变的患者临床资料,根据不同病变类型将其分为子宫内膜息肉组( n =209)、子宫内膜增生组( n =47)、子宫内膜癌组( n =32)。收集患者的临床资料,回顾性分析影响乳腺癌术后接受内分泌治疗患者发生子宫内膜癌的危险因素。【结果】三组患者的年龄、子宫内膜厚度、绝经和异常子宫出血之间差异有统计学意义( P <0.05);子宫内膜厚度、绝经和异常子宫出血为乳腺癌术后接受内分泌治疗患者发生子宫内膜癌的独立危险因素( P <0.05);子宫内膜厚度≥7.760 mm时,预测子宫内膜癌的灵敏度为59.4%,特异度为73.9%,绝经和异常子宫出血预测子宫内膜癌的灵敏度分别为75.0%、71.9%,特异度分别为39.1%、24.5%。【结论】乳腺癌术后接受内分泌治疗的患者绝经、异常子宫出血和子宫内膜厚度≥7.760 mm均为发生子宫内膜癌的独立危险因素。
Abstract：【Objective】To analyze the risk factors of endometrial cancer in patients undergoing endocrine therapy after breast cancer surgery. 【Methods】The clinical data of 288 patients with endometrial lesions after endocrine therapy in our hospital from January 2015 to March 2020 were retrospectively analyzed. According to different types of lesions, they were divided into endometrial polyps group ( n =209), endometrial hyperplasia group ( n =47) and endometrial carcinoma group ( n =32). The risk factors of endometrial cancer were analyzed retrospectively. 【Results】There were significant differences in age, endometrial thickness, menopause and abnormal uterine bleeding among the three groups ( P <0.05); endometrial thickness, menopause and abnormal uterine bleeding were independent risk factors for endometrial cancer in patients receiving endocrine therapy after breast cancer surgery ( P <0.05); when endometrial thickness ≥ 7.760 mm, the sensitivity of predicting endometrial cancer was 59.4%,the specificity was 73.9%, the sensitivity of menopause and abnormal uterine bleeding in predicting endometrial cancer was 75.0% and 71.9% respectively.The specificity was 39.1% and 24.5% respectively.【Conclusion】Menopause, abnormal uterine bleeding and endometrial thickness ≥ 7.760 mm were independent risk factors for endometrial cancer in patients receiving endocrine therapy after breast cancer surgery.
韩文鹤, 王晓彤, 陈艳丽. 乳腺癌术后接受内分泌治疗的患者发生子宫内膜癌的危险因素分析[J]. 医学临床研究, 2021, 38(3): 428-430.
HAN Wen-he, WANG Xiao-tong, CHEN Yan-li. Risk factors of Endometrial Cancer in Patients Receiving Endocrine Therapy after Breast Cancer Surgery. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 428-430.
[1] 李贺,郑荣寿,张思维,等. 2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3): 166-171. [2] Burstein HJ, Lacchetti C, Anderson H, et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol, 2019,37(5):423-438. [3] Burstein HJ.Adjuvant endocrine therapy for women with hormone receptorpositive breast cancer: american society of clinical oncology clinical practice guideline focused update[J]. J Clin Oncol, 2014,32:2255-2269. [4] Davies C.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013,381(9869):805-816. [5] Kyvernitakis I, Kostev K, Hadji P.The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre-and postmenopausal women with breast cancer[J]. Osteoporos Int, 2018,29(11):2557-2564. [6] Chen JY.Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study[J]. J Cancer, 2014, 5(2):151-155. [7] Ng HS, Koczwara B, Roder D, Niyonsenga T, et al . Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study[J]. J Comorb, 2018,8(1):16-24. [8] Hernandez Ramon EE, Sandoval NA, John K, et al .Tamoxifen DNA adduct formation in monkey and human Tamoxifen DNA adduct formation in monkey and human reproductive organs[J]. Carcinogenesis, 2014, 35(5):1172-1176. [9] Fleming CA, Heneghan HM, O'Brien D, et al . Meta analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy[J]. Br J Surg, 2018,105(9):1098-1106. [10] Saccardi C, Gizzo S, Patrelli TS, et al . Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study[J]. Endocr Relat Cancer, 2013, 20(4): 455-462.
2021, Vol. 38 
